About me

Scientist with expertise in early-stage drug discovery, integrating structural biology, medicinal chemistry, and computational design to identify and develop novel chemical entities (NCEs).
I facilitate drug discovery through close collaboration across structural biology, biophysical and biochemical assays, high-throughput screening (HTS), and computational chemistry, advancing therapeutic development.
Specific and proven expertiseScientist with expertise in early-stage drug discovery, integrating structural biology, medicinal chemistry, and computational design to identify and develop novel chemical entities (NCEs).
I facilitate drug discovery through close collaboration across structural biology, biophysical and biochemical assays, high-throughput screening (HTS), and computational chemistry, advancing therapeutic development.

Specific and proven expertise
• Gene-to-structure pipeline • Biophysics • X-ray crystallography (Protein and small molecule) • NMR spectroscopy (Protein and small molecule structure and screening) • Computational medicinal chemistry • Supramolecular chemistry • Inorganic chemistry • Organic synthesis • Analytical chemistry, etc.

Recent research
■ Target Enabling Packages (TEPs) (Gates Foundation-Funded Initiatives)
■ Led and contributed to integrated drug discovery programs focused on advancing gene-to-structure-to-chemical probe pipelines. Collaborated across multidisciplinary teams—including academic and industry partners—to accelerate the development of novel therapeutics and chemical tools.

■ Core Expertise
• Structure-Based Drug Design: Applied X-ray crystallography, NMR spectroscopy, and complementary biophysical methods (ITC, DSF/FTSA, MST, DLS, FRET) to guide molecular optimization and validate target engagement.
• Fragment-Based Drug Discovery (FBDD): Established and led FBDD platforms, executing multiple campaigns from fragment screening to hit expansion and lead development.
• Computational Medicinal Chemistry: Utilized molecular modeling, docking, and structure-guided design to support hit-to-lead optimization and dual-target inhibitor development.

■ Main contributions
• Antiviral Lead Optimization: Designed and refined an antiviral compound using computational and crystallographic approaches, achieving sub-micromolar Kd and IC₅₀ values.
• Dual Inhibitor Design: Independently developed a dual-target inhibitor by integrating crystallographic data to enhance molecular interactions and improve selectivity.
• BRCA1 tBRCT Domain Targeting: Conducted NMR-based fragment screening, followed by crystallization and structure-guided fragment expansion to improve binding affinity.
• Protein Class Diversity: Led fragment screening campaigns across diverse protein families, identifying novel scaffolds and enabling rational probe development.
• Binding Site Characterization: Performed backbone assignment and mapped binding pockets of fragment hits, facilitating precise interaction profiling and downstream SAR efforts.
• Cross-Platform Integration: Merged structural biology insights with biophysical validation to support rational design and accelerate probe development.



Valid HTML! Valid CSS! updated: 01.01.25 | © prasadtk | visits: